NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,175 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $3.52, for a total value of $21,736.00. Following the completion of the sale, the chief operating officer now owns 89,690 shares of the company’s stock, valued at approximately $315,708.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ronald Allen Louks also recently made the following trade(s):
- On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The shares were sold at an average price of $3.03, for a total value of $15,892.35.
- On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The shares were sold at an average price of $3.39, for a total value of $22,729.95.
Shares of NantHealth Inc (NASDAQ NH) traded up $0.29 during trading on Tuesday, hitting $3.90. The stock had a trading volume of 265,471 shares, compared to its average volume of 191,617. The firm has a market capitalization of $406.45 and a price-to-earnings ratio of -2.67. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93. NantHealth Inc has a 12 month low of $2.60 and a 12 month high of $10.26.
A number of equities research analysts have recently issued reports on NH shares. Zacks Investment Research lowered NantHealth from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Jefferies Group reaffirmed a “buy” rating and set a $5.00 target price on shares of NantHealth in a research report on Thursday, September 28th. Canaccord Genuity cut their target price on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. Finally, BidaskClub lowered NantHealth from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $7.90.
Large investors have recently bought and sold shares of the stock. Alliancebernstein L.P. acquired a new position in NantHealth during the second quarter valued at $102,000. GSA Capital Partners LLP acquired a new position in NantHealth during the second quarter valued at $121,000. Teachers Advisors LLC raised its position in NantHealth by 351.8% during the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares during the period. California State Teachers Retirement System raised its position in NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after buying an additional 18,000 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new position in NantHealth during the third quarter valued at $180,000. 7.10% of the stock is currently owned by hedge funds and other institutional investors.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
What are top analysts saying about NantHealth? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NantHealth and related companies.